# iCellate Medical AB: Medical practice, Solna, Sweden

> iCellate Medical AB: iCellate Medical AB is a Swedish life-science company established in 2011, specializing in cancer diagnostics and precision oncology...

Source: https://millionrounds.com/startup/icellate-medical-ab (Millionrounds; every figure on the page links to its filing or article)

Sweden · [Medical practice startup](https://millionrounds.com/companies)

# iCellate Medical AB

iCellate Medical AB is a Swedish life-science company established in 2011, specializing in cancer diagnostics and precision oncology services.

Funding reported Last round: Venture (Round not Specified)

Medical practice Solna, Sweden

Company summary

- **Founded:** 2011 15 years old
- **Team:** 10 1 to 10 people
- **Funding reported:** 9.8M as listed, currency not stated
- **Last round:** Venture (Round not Specified) Jun 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for iCellate Medical AB has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About iCellate Medical AB

iCellate Medical AB is a Swedish life-science company established in 2011, specializing in cancer diagnostics and precision oncology services.

Headquartered in Solna/Stockholm, the company originated from research at the Karolinska Institute, collaborating with Karolinska University Hospital and KTH. The company focuses on cancer profiling throughout the cancer lifecycle, including hereditary cancer risk assessment, early detection, treatment selection, and monitoring. Its platform analyzes tumor-derived material from blood samples, such as circulating tumor cells and genomic DNA, to assist clinicians in detecting cancer earlier and making personalized treatment decisions. Key offerings include the CellMate® platform for cancer cell detection, GeneMate® for hereditary cancer testing, liquid biopsy-based diagnostic services, and a companion diagnostic test for Ewing sarcoma. iCellate serves a diverse customer base, including clinicians, healthcare organizations, academic institutions, and pharmaceutical companies, primarily in Europe and North America. Its solutions are utilized in both research and clinical settings to advance personalized medicine and cancer studies.

## What company datasets say iCellate Medical AB raised

Funding, as reported

Reported in all **9.8M** in the source's currency

Last round **Venture (Round not Specified)**

Last round size **2.4M**

Last round date **Jun 2023**

## The company, in detail

What they build

Known for

liquid biopsy hospital & health care b2c medical practice early detection services cdx hereditary cancer next generation sequencing solid tumors b2b circulating tumor cells cancer diagnostics medical & diagnostic laboratories cancer

Built with from their website

LiteSpeed Viewport Meta Google Font API Mobile Friendly Bootstrap PHP Litespeed Cache Twitter Sharing

- **Sector:** Medical practice
- **Industry code:** NAICS 541714, 621511
- **Region:** Stockholm County

## Medical practice in Sweden

Startups like it

- [**Min Doktor** Malmö · founded 2013](https://millionrounds.com/startup/min-doktor)
- [**Knodd** Gothenburg · founded 2018](https://millionrounds.com/startup/knodd)
- [**Vlg - Väsby Läkargrupp** Upplands Vaesby](https://millionrounds.com/startup/vlg-v-sby-l-kargrupp)
- [**ISOREA AB** Gothenburg · founded 2022](https://millionrounds.com/startup/isorea-ab)
- [**Deep-med AB** Stockholm · founded 2016](https://millionrounds.com/startup/deep-med-ab)

## Is this your company?

Add your raise, your deck and your story, and put iCellate Medical AB in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)